Systemic sarcoidosis reactions as a result of tumour necrosis factor-alpha treatment for patients with psoriasis.
Adalimumab
/ adverse effects
Etanercept
/ adverse effects
Female
Humans
Kidney Diseases
/ chemically induced
Male
Middle Aged
Psoriasis
/ drug therapy
Sarcoidosis
/ chemically induced
Sarcoidosis, Pulmonary
/ chemically induced
Tumor Necrosis Factor Inhibitors
/ adverse effects
Tumor Necrosis Factor-alpha
/ antagonists & inhibitors
Journal
Clinical and experimental dermatology
ISSN: 1365-2230
Titre abrégé: Clin Exp Dermatol
Pays: England
ID NLM: 7606847
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
accepted:
18
05
2021
pubmed:
23
5
2021
medline:
4
2
2022
entrez:
22
5
2021
Statut:
ppublish
Résumé
The high efficacy and tolerability of biological therapies such as anti-tumour necrosis factor-alpha (TNF-α) have transformed outcomes for many inflammatory conditions. Conversely, a wide range of paradoxical reactions, including pulmonary, renal and ocular sarcoidosis secondary to TNF-α blocking agents in patients with severe psoriasis, has been reported. Sarcoid-like granulomatosis is one of these reactions, which may affect the pulmonary and cutaneous systems. Renal and ocular sarcoidosis, however, are less frequent and have unknown consequences. In this report, we present two cases of anti-TNF-α-induced sarcoidosis involving the pulmonary and renal systems.
Substances chimiques
Tumor Necrosis Factor Inhibitors
0
Tumor Necrosis Factor-alpha
0
Adalimumab
FYS6T7F842
Etanercept
OP401G7OJC
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1548-1550Informations de copyright
© 2021 British Association of Dermatologists.
Références
Decock A, Assche GV, Vermeire S et al. Sarcoidosis-like lesions: another paradoxical reaction to anti-TNF therapy? J Crohn Colitis 2017; 11: 378-83.
Wendling D, Prati C. Paradoxical effects of anti-TNF-α agents in inflammatory diseases. Exp Rev Clin Immunol 2014; 10: 159-69.
Thavarajah K, Wu P, Rhew EJ et al. Pulmonary complications of tumor necrosis factor-targeted therapy. Respir Med 2009; 103: 661-9.
Daïen CI, Monier A, Claudepierre P. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology 2009; 48: 883-6.
Sandys V, Moloney B, Lane L et al. Granulomatous interstitial nephritis secondary to adalimumab therapy. Clin Kidney J 2018; 11: 219-21.
Toussirot E, Pertuiset E. TNFα blocking agents and sarcoidosis: an update. Rev Méd Interne 2010; 31: 828-37.
Hostettler KE, Studler U, Tamm M et al. Long-term treatment with infliximab in patients with sarcoidosis. Respiration 2012; 83: 218-24.
Pritchard C, Nadarajah K. Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients. Ann Rheum Dis 2004; 63: 318-20.
Korsten P, Sweiss NJ, Nagorsnik U et al. Drug-induced granulomatous interstitial nephritis in a patient with ankylosing spondylitis during therapy with adalimumab. Am J Kidney Dis 2010; 56: 17-21.